本公告僅供參考，並不構成收購、購買或認購本公告所提述的本公司證券的邀請或要約。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 GENOR BIOPHARMA HOLDINGS LIMITED 嘉和生物藥業（開曼）控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6998） 公告 (1)非常重大收購事項及關連交易－合併附屬公司與 標的公司之間涉及根據特定授權發行代價股份的建議合併； (2)涉及新上市申請的反向收購； (3)申請清洗豁免； (4)有關股東人員留任計劃的特別交易； (5)建議更改公司名稱； 股東及潛在投資者應注意，合併完成須待合併先決條件獲達成或豁免（視情況而 定）後，方可作實。此外，聯交所上市委員會未必會批准本公司提出的新上市申 請。倘若新上市申請不獲批准，合併協議將不會成為無條件，而建議合併將不會 進行。 執行人員可以授予或不授予清洗豁免。獲授予清洗豁免是合併先決條件之一。倘 執行人員未授予清洗豁免，或清洗豁免及建議合併未於 ...

Group 1 - The majority of Hong Kong biotech stocks experienced declines, with notable drops in several companies [1] - Specifically, Gilead Sciences fell by 15.06%, while Yunkang Group and Pigeon BioPharma dropped over 14% and 9% respectively [2] - Other companies such as China Antibody and Jiahua Bio also saw declines exceeding 7% [1][2] Group 2 - The latest market prices and total market capitalizations for the affected companies include: - Gilead Sciences at 15.510 with a market cap of 14.946 billion - Yunkang Group at 2.300 with a market cap of 1.429 billion - Pigeon BioPharma at 31.760 with a market cap of 12.258 billion - Tengsheng BioPharma at 2.210 with a market cap of 1.590 billion - China Antibody at 3.210 with a market cap of 4.371 billion - Jiahua Bio at 4.460 with a market cap of 2.347 billion [2]

Summary of Key Points Core Viewpoint - The Hong Kong biotechnology sector experienced a significant decline, with most stocks falling sharply, indicating a bearish trend in the market [1]. Company Performance - **Gilead Sciences (歌礼制药-B)**: Decreased by 15.06%, latest price at 15.510, market cap at 14.946 billion [2]. - **Yunkang Group (云康集团)**: Fell by 14.18%, latest price at 2.300, market cap at 1.429 billion [2]. - **PAG Pharmaceuticals (派格生物医药-B)**: Dropped by 9.15%, latest price at 31.760, market cap at 12.258 billion [2]. - **Tengsheng Boao (腾盛博药-B)**: Declined by 8.30%, latest price at 2.210, market cap at 1.590 billion [2]. - **China Antibody (中国抗体-B)**: Decreased by 7.49%, latest price at 3.210, market cap at 4.371 billion [2]. - **Jiahua Biotech (嘉和生物-B)**: Fell by 7.08%, latest price at 4.460, market cap at 2.347 billion [2]. - **Sillod Pharmaceuticals (思路迪医药股份)**: Dropped by 6.06%, latest price at 7.910, market cap at 2.042 billion [2]. - **Tiger Med (泰格医药)**: Decreased by 5.73%, latest price at 54.250, market cap at 46.711 billion [2]. - **Kangji Medical (加科思-B)**: Fell by 5.69%, latest price at 8.120, market cap at 6.404 billion [2]. - **WuXi AppTec (药明巨诺-B)**: Dropped by 5.14%, latest price at 5.720, market cap at 2.382 billion [2]. - **Three Leaf Clover Biotech (三叶草生物-B)**: Decreased by 5.13%, latest price at 0.740, market cap at 0.960 billion [2]. - **Yiming Oncology (宜明昂科-B)**: Fell by 4.76%, latest price at 12.810, market cap at 5.218 billion [2]. - **Junshi Biosciences (君实生物)**: Decreased by 4.69%, latest price at 34.540, market cap at 35.462 billion [2]. - **Zhonghui Biotech (中慧生物-B)**: Fell by 4.39%, latest price at 51.150, market cap at 20.125 billion [2]. - **Zhaoyan New Drug (昭衍新药)**: Decreased by 4.38%, latest price at 23.140, market cap at 17.343 billion [2].

格隆汇8月13日丨嘉和生物-B(06998.HK)公布，公司将于2025年8月27日召开董事会会议，以（其中包 括）审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 GENOR BIOPHARMA HOLDINGS LIMITED 嘉和生物藥業（開曼）控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6998） 董事會會議召開日期 嘉和生物藥業（開曼）控股有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本 公司謹定於2025年8月27日（星期三）舉行董事會會議，以考慮及批准（其中包括） 本公司及其附屬公司截至2025年6月30日止六個月的中期業績及其發佈。 承董事會命 嘉和生物藥業（開曼）控股有限公司 執行董事及首席財務官 翁承毅先生 香港，2025年8月13日 於本公告日期，董事會由六(6)名董事組成，即執行董事翁承毅先生（首席財務 官）；非執行董事于鐵銘先生及劉逸先生；及獨立非執行董事崔白女士、馮冠豪先 生及陳文先生。 ...

Core Viewpoint - 嘉和生物-B (06998) announced the issuance of 225,800 shares as part of the restricted share unit plan adopted on June 3, 2021 [1] Group 1 - The company selected participants for the restricted share unit plan [1] - The issuance of shares is in accordance with the plan established in 2021 [1]

Group 1 - The company, 嘉和生物-B (06998), announced the issuance of 225,800 shares as part of its restricted share unit plan adopted on June 3, 2021 [1]

FF305 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 嘉和生物藥業（開曼）控股有限公司 呈交日期： 2025年8月7日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06998 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份） ...

Group 1 - The core point of the article is that Jiahe Biotech-B (06998) experienced a significant stock price increase of over 17%, reaching 3.76 HKD with a trading volume of 22.33 million HKD, following the announcement of a new clinical trial for its drug GB268 [1][1][1] - The clinical trial is a Phase I study evaluating the safety, tolerability, pharmacokinetics, and efficacy of the PD-1/CTLA-4/VEGF tri-specific antibody GB268 in patients with advanced solid tumors [1][1][1] - GB268 is an independently developed tri-specific antibody by Jiahe Biotech targeting PD-1, VEGF, and CTLA-4 [1][1][1] Group 2 - On April 15, Jiahe Biotech announced that it has submitted a listing application to the Hong Kong Stock Exchange, and Eton Pharmaceuticals will reverse acquire Jiahe Biotech [1][1][1] - In October 2024, Jiahe Biotech and Eton Pharmaceuticals announced a strategic merger, after which the company will be renamed "Eton Jiahe Pharmaceutical Group Limited" [1][1][1] - As part of the merger, Jiahe Biotech will issue new shares to Eton Pharmaceuticals' shareholders, with the equity values of Eton Pharmaceuticals and Jiahe Biotech being 677 million USD and 197 million USD, respectively [1][1][1]

消息面上，药物临床试验登记与信息公示平台数据显示，嘉和生物的一项在晚期实体瘤患者中评价PD- 1/CTLA-4/VEGF三特异性抗体GB268的安全性、耐受性、药代动力学和疗效的首次人体、开放性、多中 心的I期研究已启动。公开资料显示，GB268是嘉和生物自主研发的一款抗PD-1/VEGF/CTLA-4三特异性 抗体。 值得注意的是，嘉和生物4月15日公告，公司已向港交所递交上市申请，亿腾医药将反向收购嘉和生 物。早在2024年10月，嘉和生物与亿腾医药宣布达成战略性合并。合并后公司更名为"亿腾嘉和医药集 团有限公司"。嘉和生物向亿腾医药股东发行新股作为对价，亿腾医药、嘉和生物在此次交易中的股权 价值分别为6.77亿美元和1.97亿美元。亿腾医药股东将持有合并公司77.43%的股份，成为合并公司的控 股股东，而嘉和生物的股东则持有其余的22.57%股份。 嘉和生物-B(06998)午后涨超17%，截至发稿，涨14.98%，报3.76港元，成交额2233.1万港元。 ...